Straits Times Index
3,278.30 -14.83 (-0.45%) Nikkei
37,628.48 -831.60 (-2.16%) Hang Seng
17,247.88 +46.61 (+0.27%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,247.57 -2,474.39 (-3.71%) CMC Crypto 200
1,391.79 +9.22 (+0.67%)
Grifols, S.A. (GRFS)
After hours:
| Previous close | 6.48 |
| Open | 6.42 |
| Bid | 6.38 x 400 |
| Ask | 6.41 x 400 |
| Day's range | 6.29 - 6.44 |
| 52-week range | 5.30 - 12.15 |
| Volume | |
| Avg. volume | 2,166,237 |
| Market cap | 5.41B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 63.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 03 Jun 2021 |
| 1y target est | N/A |
- Reuters
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
- Reuters
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday. Grifols did not specify the amount due next year. Since January, the Spanish drug maker's debt sustainability has been questioned by short seller Gotham City Research.
- Reuters
Spain's supervisor CNMV finds no significant errors in Grifols accounts
Beleaguered Spanish drugmaker Grifols will not be required to restate its accounts for the years 2021 and 2022, market supervisor CNMV said on Thursday, as its investigation found no significant errors in the amounts it had reported. CNMV also found "no evidence that the financial debt reported by Grifols does not correspond to reality," it said. Since early January, short-sheller Gotham City Research had released three reports repeatedly accusing Grifols of overstating earnings and understating debt in its financial accounts.
